Bullish on Gland Pharma as the company appears to be entering a stronger phase of growth,

$GLAND Supported by improving execution, margin expansion and a recovery in its international business. The company’s Q3 FY26 performance was particularly encouraging, with revenue growing 22% YoY, adjusted EBITDA rising 25% and adjusted PAT increasing 37% YoY, while adjusted EBITDA margin reached 26%. The turnaround of Cenexi, which reached EBITDA breakeven, is another important positive because further operational improvement can support consolidated profitability. Alongside this, Gland’s core business continues to benefit from new product launches, CDMO opportunities, technology transfers and growth across markets such as the US, Europe and India. The company is also continuing to invest heavily in R&D, creating a pipeline that could support future launches and longer-term growth. With revenue growth accelerating, margins improving and multiple potential growth levers coming together, I believe Gland Pharma offers an interesting long-term pharmaceutical story. The key factors I would track going forward are sustainability of growth, Cenexi’s profitability, new product launches, regulatory outcomes and valuation. This is a bullish view, not a guarantee of returns, and investors should evaluate the risks and valuation before taking any position.